Veru (VERU)
NASDAQ:VERU
Enobosarm, Semaglutide Weekly Injection
Obesity & Overweight, Mobility Disability, Homa-Ir
Phase II
Not Yet Recruiting
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Feb 25, 2026
―
Sabizabulin, Exemestane Monotherapy, Exemestane Plus Everolimus, Or Selective Estrogen Receptor Modulator
Metastatic Breast Cancer
Phase II
Withdrawn
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
Oct 01, 2021
―
Enobosarm & Abemaciclib Combo, Non-Steroidal Ai, Or Steroidal Ai Or Fulvestrant
Metastatic Breast Cancer
Phase III
Terminated
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
Sep 21, 2021
―
Sacituzumab Govitecan-Hziy, Sabizabulin, Sabizabulin/Sacituzumab Govitecan-Hziy Combo
Metastatic Triple Negative Breast Cancer
Phase II
Withdrawn
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
Aug 10, 2021
―
Exemestane, Enobosarm
Metastatic Breast Cancer
Phase III
Terminated
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
Apr 27, 2021
―
Veru-111
Sars-Cov Infection
Phase III
Completed
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
Apr 09, 2021
―
Veru-100
Advanced Prostate Adenocarcinoma
Phase I/II
Terminated
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
Apr 09, 2021
―
Veru-111, Enzalutamide, Abiraterone
Metastatic Castration-Resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Phase III
Terminated
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Apr 09, 2021
―
Veru-111
Respiratory Distress Syndrome, Adult
Phase II
Completed
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
May 13, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Veru (VERU) have in its pipeline
VERU is currently developing the following drugs: Enobosarm, Semaglutide Weekly Injection, Semaglutide, Enobosarm, Sabizabulin, Exemestane Monotherapy, Exemestane Plus Everolimus, Or Selective Estrogen Receptor Modulator. These drug candidates are in various stages of clinical development as the company works toward FDA approval.